• Tajana Filipec Kanižaj, Petra Dinjar Kujundžić, Ana Ostojić, Maja Mijić, Helga Sertić Milić, Ana Mijić, Matija Mateljak, Dora Martinčević, Eva Radetić, Vinko Vidjak, Branislav Kocman, and Ivana Mikolašević.
• Tajana Filipec Kanižaj, Department of Gastroenterology, Merkur University Hospital, Zajčeva 19, 10000 Zagreb, Croatia, tajana.filipec@gmail.com.
• Croat. Med. J. 2022 Aug 31; 63 (4): 317-325.

AimTo compare the long-term outcomes between liver transplant (LT) recipients with hepatocellular carcinoma (HCC) who were downstaged with transarterial-chemoembolization (TACE) to the Milan criteria (MC) and those initially meeting the MC.MethodsThis retrospective study enrolled 198 patients with HCC: 38 were downstaged and 160 patients initially met the MC. Post-LT survival and HCC recurrence-free survival were evaluated. We assessed the association of death and HCC recurrence with TACE, baseline (age, sex, disease etiology, Model of End-stage Liver Disease, tumor number and the sum of maximum tumor diameters, waiting time, alpha-fetoprotein level) and explant characteristics (tumor number and the sum of maximum tumor diameters, micro- and macrovascular invasion).ResultsThe recipient survival rates one, three, and five years after LT were 88.2%, 80.1%, and 75.9%, respectively. HCC recurrence-free probabilities were 92.3%, 87.9%, and 85%, respectively. The outcomes were comparable between the groups. In multivariate analysis, the number of tumors on the explant, age, and tumor recurrence were independent risk factors for death. Only the sum of maximum tumor diameters on the explant was an independent risk factor for HCC recurrence.ConclusionsPatients successfully downstaged with TACE to the MC can achieve post-LT recipient and HCC recurrence-free survival comparable with patients initially within the MC. Good response to TACE as a criterion for LT may be a method of selecting patients with favorable biological characteristics.

23 keywords...

hide…